PLUVICTO®
lutetium Lu 177 vipivotide tetraxetan
INJECTION FOR INTRAVENOUS USE

MENU

EXPERIENCE PLUVICTO®

The first and only PSMA-targeted radioligand therapy, with ~20K patients treated from launch to date[1,2]

Explore our commitment to an exceptional PLUVICTO experience for you and your patients

Indication

PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibition (ARPI) therapy, and

- are considered appropriate to delay taxane-based chemotherapy, or
- have received prior taxane-based chemotherapy

IMPORTANT SAFETY INFORMATION

Risk From Radiation Exposure

PLUVICTO contributes to a patient's long-term cumulative radiation exposure, which is associated with an increased risk for cancer.

Minimize radiation exposure to patients, medical personnel, and others during and after treatment with PLUVICTO consistent with institutional practices, patient treatment procedures, Nuclear Regulatory Commission patient-release guidance, and instructions to the patient for follow-up radiation protection.

PSMA, prostate-specific membrane antigen.

Please see Important Safety Information on pages 8-10 and full Prescribing Information.

NEXT

MENU

Please see Important Safety Information on pages 8-10 and full Prescribing Information.

WE ARE COMMITTED TO EXPANDING CAPACITY TO SERVE EVEN MORE PATIENTS

~20K

PATIENTS TREATED WITH PLUVICTO FROM LAUNCH TO DATE[2,*]

With unconstrained supply, we've increased production for faster, on-time delivery of PLUVICTO to meet current and future demand

- There are **2 state-of-the-art manufacturing sites** for PLUVICTO in the United States (New Jersey and Indiana), **with planned expansion to California** to support all West Coast needs
- PLUVICTO can be **delivered within 5 days of order placement**,[†] so your patients can begin treatment as soon as possible[3]

~99%

ON-TIME DELIVERY FOR ALL PLUVICTO ORDERS[4]

~66K

DOSES SHIPPED FROM LAUNCH TO DATE[2,‡]

PRODUCT ORDERING SUPPORT IS AVAILABLE BY CALLING **1-844-367-3222**, MONDAY-FRIDAY, 6:00 AM-8:00 PM ET, EXCLUDING HOLIDAYS

*Based on data from February 2025.

†Exceptions may apply for syringe form and select geographic locations.[3]

‡US commercial orders only.

Please see Important Safety Information on pages 8-10 and full Prescribing Information.

THE NUMBER OF PLUVICTO TREATMENT SITES CONTINUES TO GROW EACH YEAR



THERE ARE OVER

600

PLUVICTO TREATMENT SITES IN THE US[2]

FIND A PLUVICTO TREATMENT CENTER ›

CONTACT YOUR DEDICATED NOVARTIS ONCOLOGY SPECIALIST FOR ADDITIONAL SUPPORT TO FIND YOUR LOCAL TREATMENT CENTER

You can search by name of practice, city, state, or ZIP code. Please note that the PLUVICTO Treatment Centers listed are only those that have authorized their participation on the PLUVICTO website. Please check back regularly, as this list will be periodically updated with newly certified locations.

Novartis Pharmaceuticals Corporation does not provide or supervise medical care furnished through these treatment centers, which are independently owned and operated.

IF YOU'RE INTERESTED IN BECOMING A TREATMENT SITE, PLEASE CONTACT OUR CUSTOMER SUPPORT TEAM AT **1-844-367-3222**, MONDAY-FRIDAY, 6:00 AM-8:00 PM ET, EXCLUDING HOLIDAYS

Please see Important Safety Information on pages 8-10 and full Prescribing Information.

PLUVICTO IS ACCESSIBLE FOR MOST INSURED PATIENTS*

100%

OF MEDICARE FFS PATIENTS ARE COVERED TO LABEL[5]

95%

OF MEDICARE ADVANTAGE PATIENTS ARE COVERED TO LABEL[5]

- **>80% of insured patients have favorable coverage for PLUVICTO as of January 2025[5]**

The other 20% do not have published policies and/or cases may be decided on an individual basis. Follow up with the patient's plan to determine coverage.

>8 of 10

COVERED PATIENTS PAID $0 OUT-OF-POCKET PER INFUSION[6]

A review of claims data between Q1 2023-Q2 2024 indicated that approximately 85% of patients paid $0 for the product. For remaining patients, the out-of-pocket cost for the product varies and may be as high as the total cost of the product. Additional out-of-pocket costs may be incurred related to treatment, including but not limited to administration fees.

Coverage determined based on patients treated with at least one ARPI and one taxane.

ARPI, androgen receptor pathway inhibitor; FFS, fee for service; OOP, out-of-pocket.

*The information provided in this communication is not a guarantee of coverage and patient OOP costs may vary. Actual coverage and reimbursement decisions are made by individual payers following the receipt of claims and will vary.

Please see Important Safety Information on pages 8-10 and full Prescribing Information.

PATIENT ACCESS LOOKUP TOOL

Patient Access Lookup Tool

A resource to help you understand patient coverage for PLUVICTO by state, payer, and plan type*

View insurance coverage for PLUVICTO

Download prior authorization forms and coverage summaries for PLUVICTO

Obtain payer contact information

GO TO THE PATIENT ACCESS LOOKUP TOOL ›

*This website provides general information and is not intended to provide reimbursement or legal advice. Furthermore, it is not intended to increase or maximize payment by any payer. Because laws, regulations, and coverage policies are complex and updated frequently, you should check with your local Medicare carrier and payers often or go to www.cms.gov.

Nothing in the information provided shall be construed as a guarantee of Novartis regarding levels of reimbursement, payment, or charge that reimbursement will be received. The ultimate responsibility for obtaining reimbursement lies with the physician, provider, or patient. Please consult with your counsel or reimbursement specialist for any practice-specific reimbursement or billing questions.

Please see Important Safety Information on pages 8-10 and full Prescribing Information.

PLUVICTO®
lutetium Lu 177 vipivotide tetraxetan
INJECTION FOR INTRAVENOUS USE

MENU

NOVARTIS PATIENT SUPPORT™: A DEDICATED TEAM FOR YOU AND YOUR PATIENTS

Novartis Patient Support is a comprehensive program designed to help your patients start, stay, and save on PLUVICTO

We provide support throughout your patient's journey with:



Insurance & Reimbursement

Support includes:
- Benefits verification
- Prior authorization requirements
- Appeals support
- Billing, coding, and reimbursement education

Financial Support

Eligible patients may pay as little as $0* per dose. Enrollment is required to determine eligibility and participation.

Acquisition

Support includes:
- New treating site onboarding and access to ordering platform
- Real-time delivery tracking

Benefit investigation can be completed in less than 2 business days.†
Click here and fax the Start Form to **1-844-638-7329**.

ASK YOUR NOVARTIS ONCOLOGY SPECIALIST TO CONNECT YOU WITH YOUR LOCAL ACCESS & REIMBURSEMENT REPRESENTATIVE TO HELP ANSWER DETAILED QUESTIONS ON PAYER COVERAGE, PATIENT AFFORDABILITY, PURCHASING, PRICING, AND REIMBURSEMENT

*Limitations apply. Valid only for those patients with commercial insurance. Not valid under Medicare or any other federal or state program. Offer subject to a maximum benefit per course of treatment. See complete Terms and Conditions in the Start Form for details.

†Primary plans only; an additional 1-2 days if secondary plan coverage review is required.

Please see Important Safety Information on pages 8-10 and full Prescribing Information.

INDICATION AND IMPORTANT SAFETY INFORMATION

Indication

PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibition (ARPI) therapy, and

- are considered appropriate to delay taxane-based chemotherapy, or
- have received prior taxane-based chemotherapy

IMPORTANT SAFETY INFORMATION

Risk From Radiation Exposure

PLUVICTO contributes to a patient's long-term cumulative radiation exposure, which is associated with an increased risk for cancer.

Minimize radiation exposure to patients, medical personnel, and others during and after treatment with PLUVICTO consistent with institutional practices, patient treatment procedures, Nuclear Regulatory Commission patient-release guidance, and instructions to the patient for follow-up radiation protection.

Ensure patients increase oral fluid intake and advise them to void as often as possible to reduce bladder radiation.

To minimize radiation exposure to others, advise patients to limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days, to refrain from sexual activity for 7 days, and to sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.

IMPORTANT SAFETY INFORMATION (continued)

Myelosuppression

PLUVICTO can cause severe and life-threatening myelosuppression. In the PSMAfore study, grade 3 or 4 decreased hemoglobin (7%), decreased leukocytes (4.4%), decreased neutrophils (3.5%), and decreased platelets (2.7%) occurred in patients treated with PLUVICTO. One death occurred due to bone marrow failure during long-term follow-up in a patient who received PLUVICTO. In the VISION study, 4 myelosuppression-related deaths occurred.

Perform complete blood counts before and during treatment with PLUVICTO. Withhold, reduce dose, or permanently discontinue PLUVICTO based on severity of myelosuppression.

Renal Toxicity

PLUVICTO can cause severe renal toxicity. In the PSMAfore study, grade 3 or 4 acute kidney injury (1.3%) occurred in patients treated with PLUVICTO.

Advise patients to remain well hydrated and to urinate frequently before and after administration of PLUVICTO. Perform kidney function laboratory tests, including serum creatinine and calculated creatinine clearance (CrCl), before and during treatment. Withhold, reduce dose, or permanently discontinue PLUVICTO based on severity of renal toxicity.

Embryo-Fetal Toxicity

The safety and efficacy of PLUVICTO have not been established in females. Based on its mechanism of action, PLUVICTO can cause fetal harm. No animal studies using lutetium Lu 177 vipivotide tetraxetan have been conducted to evaluate its effect on female reproduction and embryo-fetal development; however, radioactive emissions, including those from PLUVICTO, can cause fetal harm. Advise males with female partners of reproductive potential to use effective contraception during treatment with PLUVICTO and for 14 weeks after the last dose.

IMPORTANT SAFETY INFORMATION (continued)

Infertility

The recommended cumulative dose of 44.4 GBq of PLUVICTO results in a radiation-absorbed dose to the testes within the range where PLUVICTO may cause temporary or permanent infertility.

Adverse Reactions and Laboratory Abnormalities

In the pooled safety population for the PSMAfore and VISION studies (N=756), the most common (≥20%) adverse reactions, including laboratory abnormalities, were decreased lymphocytes (83%), decreased hemoglobin (65%), fatigue (49%), dry mouth (46%), decreased platelets (40%), decreased estimated glomerular filtration rate (37%), nausea (35%), decreased neutrophils (31%), decreased calcium (29%), decreased sodium (27%), increased aspartate aminotransferase (26%), increased alkaline phosphatase (24%), arthralgia (22%), decreased appetite (21%), increased potassium (21%), constipation (21%), and back pain (21%).

Please see full Prescribing Information.

References: 1. Pluvicto. Prescribing information. Novartis Pharmaceuticals Corp. **2.** Data on file. NPS Numbers. Novartis Pharmaceuticals Corp; 2025. **3.** Data on file. Order Lead Time. Novartis Pharmaceuticals Corp; 2025. **4.** Data on file. Novartis Technical Operations. Novartis Pharmaceuticals Corp; 2024. **5.** Data on file. MMIT Market Access Claims. March 2025. **6.** Data on file. PLUVICTO IQVIA LAAD data analysis. Novartis Pharmaceuticals Corp; Jan 2023 to Jun 2024.

PLUVICTO®
lutetium Lu 177 vipivotide tetraxetan
INJECTION FOR INTRAVENOUS USE

MENU

WE ARE COMMITTED TO DELIVERING AN EXCEPTIONAL PLUVICTO EXPERIENCE FOR YOU AND YOUR PATIENTS

PLUVICTO—the first and only PSMA-targeted radioligand therapy, with ~20K patients treated from launch to date[1,2]

- There are over 600 PLUVICTO Treatment Centers in the US[2]
- PLUVICTO can be delivered within 5 days of order placement[3]

FIND A PLUVICTO TREATMENT CENTER ›

GO TO THE PATIENT ACCESS LOOKUP TOOL ›

Novartis Patient Support provides comprehensive resources designed to help your patients start, stay, and save on PLUVICTO

- Questions? Call Novartis Patient Support at 1-844-638-7222, Monday-Friday, 8:00 AM-8:00 PM ET, excluding holidays

Indication

PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibition (ARPI) therapy, and

- are considered appropriate to delay taxane-based chemotherapy, or
- have received prior taxane-based chemotherapy

IMPORTANT SAFETY INFORMATION

Risk From Radiation Exposure

PLUVICTO contributes to a patient's long-term cumulative radiation exposure, which is associated with an increased risk for cancer.

Minimize radiation exposure to patients, medical personnel, and others during and after treatment with PLUVICTO consistent with institutional practices, patient treatment procedures, Nuclear Regulatory Commission patient-release guidance, and instructions to the patient for follow-up radiation protection.

Please see Important Safety Information on pages 8-10 and full Prescribing Information.

NOVARTIS

PLUVICTO®
lutetium Lu 177 vipivotide tetraxetan
INJECTION FOR INTRAVENOUS USE

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

3/25 FA-11348516

PREVIOUS